Group 1 - The core viewpoint of the news is that Hutchison China MediTech has completed patient enrollment for the SANOVO Phase III study, which evaluates the combination therapy of savolitinib and osimertinib for specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1][2] - The SANOVO study is a randomized controlled trial assessing the efficacy and safety of the combination therapy compared to osimertinib monotherapy, which is the current standard treatment for these patients [1] - The primary endpoint of the study is progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety [1] Group 2 - Topline results from the SANOVO study are expected to be announced in the second half of 2026, followed by submission of the results to appropriate academic conferences [2] - If the results are favorable, Hutchison China MediTech plans to submit a new indication application to the National Medical Products Administration of China [2] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor developed jointly by AstraZeneca and Hutchison China MediTech, while osimertinib is characterized as an irreversible third-generation EGFR TKI [2]

Core Viewpoint - The approval of the combination therapy of Savolitinib (ORPATHYS®) and Osimertinib (TAGRISSO®) by the National Medical Products Administration of China represents a significant advancement in the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations and MET amplification after prior EGFR TKI therapy [1][2]. Company Summary - Hutchison China MediTech Limited (和黄医药) announced the approval of its combination therapy, which is a milestone in addressing the challenges faced by NSCLC patients in China [2]. - The approval will trigger a milestone payment of $11 million from AstraZeneca, which is responsible for the sales of both drugs in China [1]. - The CEO of Hutchison China MediTech emphasized the importance of collaboration with AstraZeneca in achieving this significant progress in treating MET-driven resistance in NSCLC patients [2]. Industry Summary - The combination therapy provides a new oral treatment option for NSCLC patients who develop MET amplification after treatment with EGFR inhibitors, addressing a critical resistance mechanism [2]. - The approval marks the third indication for Savolitinib in China, highlighting the ongoing development and expansion of treatment options for lung cancer patients [2].